Zura Bio (ZURA) Q3 2026 earnings summary

Executive summary

• Tibulizumab Phase 2 trials in HS and SSc completed enrollment above target; TibuSHIELD topline results are expected in Q4 2026 and TibuSURE results in H1 2027.

• FDA cleared the IND for the Phase 2 NEXUS-PMR study, planned to begin by year-end 2026; no product revenue to date.

• Q3 2026 net loss was $25.8M; cash and cash equivalents were $187.7M at September 30, with funding projected through at least end-2028.

Financial highlights

• Q3 operating expenses rose 47% YoY to $28.8M and net loss rose 43% to $25.8M, partly offset by $1.7M in net other income.

• 9M operating expenses rose 47% YoY to $83.6M; net loss rose 48% to $76.4M, including a $1.3M income tax benefit.

• Q3 R&D expense increased 63% YoY to $19.5M from $11.9M; G&A rose to $9.3M from $7.6M, reflecting higher share-based compensation and professional fees.

• 9M cash used in operations was $59.3M versus $42.5M; financing provided $137.6M, and cash increased $78.2M to $187.7M.

Outlook and guidance

• Cash and cash equivalents are expected to fund operating expenses and capital requirements through at least end-2028, subject to assumptions and changing circumstances.

• TibuSHIELD topline results are expected in Q4 2026, including the Week 16 primary endpoint; TibuSURE topline results are expected in H1 2027, including the Week 24 mRSS primary endpoint.

• The Phase 2 NEXUS-PMR study is planned to begin by year-end 2026; R&D and G&A expenses are expected to rise as development and operations expand.